Alexion Korea selects Wolman disease treatment as first drug to introduce

Alexion, a U.S. rare disease pharmaceutical company getting ready for its Korean branch, has decided the first pharmaceutical product to introduce in the domestic market.

It is Kanuma(sebelipase- α), a new biomedicine for lysosomal acid lipase deficiency(LAL-D), also known as Wolman disease.

On the 23^rd, the Ministry of Food and Drug Safety approved the domestic commercialization of Kanuma, a...